EGFR and non-small cell lung carcinoma: A recent retrospective study comparing osimertinib and durvalumab as maintenance after chemoradiotherapy in patients with stage III unresectable NSCLC and sensitizing EGFR mutation suggested that consolidation osimertinib was associated with a significantly longer PFS [55].